These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3022837)

  • 1. Conformational considerations in the design of glucagon agonists and antagonists: examination using synthetic analogs.
    Hruby VJ; Krstenansky J; Gysin B; Pelton JT; Trivedi D; Mckee RL
    Biopolymers; 1986; 25 Suppl():S135-55. PubMed ID: 3022837
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of histidine-1 in glucagon action.
    Unson CG; Macdonald D; Merrifield RB
    Arch Biochem Biophys; 1993 Feb; 300(2):747-50. PubMed ID: 8382034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic peptide antagonists of glucagon.
    Unson CG; Andreu D; Gurzenda EM; Merrifield RB
    Proc Natl Acad Sci U S A; 1987 Jun; 84(12):4083-7. PubMed ID: 3035568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon antagonists: contribution to binding and activity of the amino-terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27.
    Unson CG; Gurzenda EM; Iwasa K; Merrifield RB
    J Biol Chem; 1989 Jan; 264(2):789-94. PubMed ID: 2536024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age related changes of glucagon binding and activity in isolated rat hepatocytes.
    Poli G; Cassader M; Chiarpotto E; Biasi F; Cecchini G; Pagano G
    Int J Tissue React; 1986; 8(5):367-71. PubMed ID: 3023252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of the C-terminal alpha-helical structure for glucagon's biological activity.
    Krstenansky JL; Zechel C; Trivedi D; Hruby VJ
    Int J Pept Protein Res; 1988 Dec; 32(6):468-75. PubMed ID: 2854536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semisynthetic D-His1,N epsilon-acetimidoglucagon: structure-function relationships.
    Mahrenholz AM; Flanders KC; Hoosein NM; Gurd FR; Gurd RS
    Arch Biochem Biophys; 1987 Sep; 257(2):379-86. PubMed ID: 2821912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon antagonists. Synthesis and inhibitory properties of Asp3-containing glucagon analogs.
    Andreu D; Merrifield RB
    Eur J Biochem; 1987 May; 164(3):585-90. PubMed ID: 3032623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and hormonal activity of [Tyr22] glucagon and [desHis1, Tyr22] glucagon.
    Lu GS; Mojsov S; Merrifield RB
    Int J Pept Protein Res; 1987 Apr; 29(4):545-57. PubMed ID: 3454664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor occupancy and adenylate cyclase activation in rat liver and heart membranes by 10 glucagon analogs modified in position 2,3, 4, 25, 27 and/or 29.
    Robberect P; Damien C; Moroder L; Coy DH; Wünsch E; Christophe J
    Regul Pept; 1988 May; 21(1-2):117-28. PubMed ID: 2839870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of glucagon, gut glucagon, vasoactive intestinal polypeptide and secretin with their membrane receptors.
    Bataille D; Rosselin G; Freychet P
    Isr J Med Sci; 1975 Jul; 11(7):687-92. PubMed ID: 169214
    [No Abstract]   [Full Text] [Related]  

  • 13. Increase in stimulatory G protein and glucagon-responsive adenylate cyclase activity in rat liver following partial hepatectomy.
    Yagami T
    Biochem Mol Biol Int; 1994 Jan; 32(1):159-66. PubMed ID: 8012281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple replacement analogues of glucagon.
    Azizeh BY; Ahn JM; Caspari R; Shenderovich MD; Trivedi D; Hruby VJ
    J Med Chem; 1997 Aug; 40(16):2555-62. PubMed ID: 9258362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.
    Hruby VJ
    Mol Cell Biochem; 1982 Apr; 44(1):49-64. PubMed ID: 6283336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-function studies on positions 17, 18, and 21 replacement analogues of glucagon: the importance of charged residues and salt bridges in glucagon biological activity.
    Sturm NS; Lin Y; Burley SK; Krstenansky JL; Ahn JM; Azizeh BY; Trivedi D; Hruby VJ
    J Med Chem; 1998 Jul; 41(15):2693-700. PubMed ID: 9667960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorescent glucagon derivatives. I. Synthesis and characterisation of fluorescent glucagon derivatives.
    Heithier H; Ward LD; Cantrill RC; Klein HW; Im MJ; Pollak G; Freeman B; Schiltz E; Peters R; Helmreich EJ
    Biochim Biophys Acta; 1988 Oct; 971(3):298-306. PubMed ID: 2844291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mobile receptor and collision coupling mechanisms for the activation of adenylate cyclase by glucagon.
    Houslay MD
    Adv Cyclic Nucleotide Res; 1981; 14():111-9. PubMed ID: 6269373
    [No Abstract]   [Full Text] [Related]  

  • 19. The structure of adenylate cyclase systems.
    Rodbell M; Lad PM; Nielsen TB; Cooper DM; Schlegel W; Preston MS; Londos C; Kempner ES
    Adv Cyclic Nucleotide Res; 1981; 14():3-14. PubMed ID: 6269384
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis of two glucagon antagonists: receptor binding, adenylate cyclase, and effects on blood plasma glucose levels.
    Gysin B; Johnson DG; Trivedi D; Hruby VJ
    J Med Chem; 1987 Aug; 30(8):1409-15. PubMed ID: 3039134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.